Group 1 - Tian Da Pharmaceutical (00455) announced that Mr. Feng Quanming has resigned as a non-executive director due to other work arrangements, effective from August 29, 2025 [1] - Mr. Zhu Haomiao has been appointed as a non-executive director, effective from August 29, 2025 [1]

Core Viewpoint - Tian Da Pharmaceutical (00455) reported a decline in revenue and an increase in losses for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - The company achieved revenue of HKD 137 million, representing a year-on-year decrease of 12.45% [1] - The loss attributable to shareholders was HKD 33.237 million, which expanded by 22.03% compared to the previous year [1] - The basic loss per share was HKD 0.0155 [1]

Group 1 - The company Tian Da Pharmaceutical (00455) reported a revenue of HKD 137 million for the first half of 2025, representing a year-on-year decrease of 12.45% [1] - The company's loss attributable to shareholders widened to HKD 33.237 million, an increase of 22.03% compared to the previous year [1] - The basic loss per share was reported at HKD 1.55 cents [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 非執行董事 鍾濤先生 朱浩淼先生 獨立非執行董事 林日輝先生 （首席獨立非執行董事） 趙崇康先生 冼彥芳博士 董事會設立4個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 卻⫍֍ջ⽚厍00455卼 董事名單與其角色和職能 自2025年8月29日起，天大藥業有限公司董事會（「董事會」）成員載列如下： 執行董事 方文權先生 （董事長兼董事總經理） 呂文生先生 | | 委員會 | | | | | | --- | --- | --- | --- | --- | --- | | | | 審核 | 薪酬 | 提名 | 風險管理 | | 董事 | | 委員會 | 委員會 | 委員會 | 委員會 | | 方文權先生 | | | M | C | M | | 呂文生先生 | | | | | | | | | M | | | | | 朱浩淼先生 | | | | | | | 林日輝先生 ...

非執行董事辭任 天大藥業有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，馮全明先生 （「馮先生」）因其他工作安排，所以辭任本公司非執行董事（「非執行董事」），自 2025年8月29日起生效。馮先生已確認，彼與董事會並無任何意見分歧，亦概無有 關彼辭任之事宜須提請本公司股東（「股東」）及香港聯合交易所有限公司（「香港聯 交所」）垂注。 董事會謹此對馮先生於其任職期間對本公司作出的寶貴貢獻表示摯誠謝意。 委任非執行董事 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全 部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 卻⫍֍ջ⽚厍00455卼 非執行董事的變更 1 朱先生於本公告日期前過去三年，概無在其證券於香港或海外任何證券市場 上市的公眾公司中擔任任何其他董事職務，彼現時亦無與本公司任何董事、監事、 高級管理人員或主要或控股股東概無任何關係。 除上文所披露者外，朱先生概無於本公司擔任任何其他職務；及概無於本公 司股份中持有香港法例第571章證券及期貨條例第XV部 ...

Group 1 - The core viewpoint of the news highlights the recent performance of Tian Da Pharmaceutical, which saw a stock price increase of 8.57% despite a decline in overall revenue and profit [1][2] - Tian Da Pharmaceutical's cumulative increase over the past month is 2.94%, and 3.55% year-to-date, underperforming the Hang Seng Index by 25.45% [2] - Financial data shows that as of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99%, and a net profit attributable to shareholders of -56.83 million yuan, a decrease of 154.07% [2] Group 2 - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The pharmaceutical and biotechnology industry has an average price-to-earnings (P/E) ratio of -2.05 times, with a median of 1.44 times; Tian Da Pharmaceutical's P/E ratio stands at -6.13 times, ranking 136th in the industry [3] - The company focuses on developing traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical sector [4] Group 3 - Tian Da Pharmaceutical is committed to building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - The company utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and aims to expand its market presence both domestically and internationally [4] - The company has established marketing centers in Shenzhen and Zhuhai, and is gradually setting up branches in the US and Europe to support its international sales and brand development [4] Group 4 - A significant event reminder includes the disclosure of the mid-year report for the fiscal year 2025 on August 28, 2025 [5]

Group 1 - The company Tian Da Pharmaceutical (00455.HK) announced that it will hold a board meeting on August 28, 2025, to approve its interim results for the six months ending June 30, 2025 [1]

天大藥業有限公司 董事長兼董事總經理 方文權 謹啓 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 卻⫍֍ջ⽚厍00455卼 董事會會議日期 天大藥業有限公司（「本公司」）之董事會（「董事會」）謹此公佈，本公司將於2025年8 月28日（星期四）舉行董事會會議，以批准（其中包括）本公司及其附屬公司截至 2025年6月30日止六個月之中期業績。 代表董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 香港，2025年8月15日 於本公告日期，本公司之執行董事為方文權先生（董事長兼董事總經理）和呂文生 先生；非執行董事為鍾濤先生和馮全明先生；而獨立非執行董事則為林日輝先生、 趙崇康先生和冼彥芳博士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | 本月底法定/註冊股本 ...

Company Overview - Tian Da Pharmaceutical focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical industry [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - Tian Da Pharmaceutical utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and expand its market reach [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% compared to the previous year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Tian Da Pharmaceutical's price-to-earnings (P/E) ratio is -4.73, ranking 138th in the industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is 2.79 [3] - The company has underperformed the Hang Seng Index, with a cumulative decline of 20.12% this year, compared to the index's increase of 19.78% [2] Industry Context - The pharmaceutical and biotechnology industry has an average P/E ratio of 2.79, with a median of 6.7 [3] - Competitors in the industry include other pharmaceutical companies with varying P/E ratios, such as Jingxin Pharmaceutical at 0.86 and Dongrui Pharmaceutical at 3.03 [3]